Company · Oakville, Ontario, Canada
Ucb Canada Inc
Everything this company holds in Health Canada’s product databases, as the company’s name is spelled there.
- Drug products (DIN)
- 34
- 34 authorized now
- Natural health products
- 0
- 0 active licences
- Medical device licences
- 0
- 0 active
- Notices of Compliance
- 54
Drug products
Authorized products first.
| Name | DIN | Status | Status since |
|---|---|---|---|
| BIMZELX | 02525267 | Marketed | |
| BIMZELX | 02525275 | Marketed | |
| BIMZELX | 02553619 | Marketed | |
| BIMZELX | 02553627 | Marketed | |
| BRIVLERA | 02452936 | Marketed | |
| BRIVLERA | 02452944 | Marketed | |
| BRIVLERA | 02452952 | Marketed | |
| BRIVLERA | 02452960 | Marketed | |
| BRIVLERA | 02452979 | Marketed | |
| BRIVLERA | 02452987 | Marketed | |
| BRIVLERA | 02452995 | Marketed | |
| CIMZIA | 02331675 | Marketed | |
| CIMZIA | 02465574 | Marketed | |
| KEPPRA | 02247027 | Marketed | |
| KEPPRA | 02247028 | Marketed | |
| KEPPRA | 02247029 | Marketed | |
| NEUPRO | 02403897 | Marketed | |
| NEUPRO | 02403900 | Marketed | |
| NEUPRO | 02403919 | Marketed | |
| NEUPRO | 02403927 | Marketed | |
| NEUPRO | 02403935 | Marketed | |
| NEUPRO | 02403943 | Marketed | |
| RYSTIGGO | 02556081 | Marketed | |
| VIMPAT | 02357615 | Marketed | |
| VIMPAT | 02357623 | Marketed | |
| VIMPAT | 02357631 | Marketed | |
| VIMPAT | 02357658 | Marketed | |
| VIMPAT | 02357666 | Marketed | |
| ZILBRYSQ | 02549220 | Marketed | |
| ZILBRYSQ | 02549239 | Marketed | |
| ZILBRYSQ | 02549247 | Marketed | |
| RYSTIGGO | 02567067 | Approved | |
| RYSTIGGO | 02567075 | Approved | |
| RYSTIGGO | 02567083 | Approved |
Notices of Compliance
Newest first.
- BRIVLERAJune 12, 2026 · NOC 37701 · Supplement to a New Drug Submission (SNDS)
- RYSTIGGOMarch 31, 2026 · NOC 37245 · Supplement to a New Drug Submission (SNDS)
- KEPPRAMarch 13, 2026 · NOC 37117 · Supplement to a New Drug Submission (SNDS)
- NEUPROFebruary 2, 2026 · NOC 36825 · Supplement to a New Drug Submission (SNDS)
- BIMZELXDecember 12, 2025 · NOC 36557 · Supplement to a New Drug Submission (SNDS)
- ZILBRYSQNovember 24, 2025 · NOC 36429 · Supplement to a New Drug Submission (SNDS)
- RYSTIGGOOctober 31, 2025 · NOC 36307 · Supplement to a New Drug Submission (SNDS)
- RYSTIGGOApril 25, 2025 · NOC 35243 · New Drug Submission (NDS)
- BIMZELXDecember 11, 2024 · NOC 34531 · Supplement to a New Drug Submission (SNDS)
- ZILBRYSQJuly 11, 2024 · NOC 33622 · New Drug Submission (NDS)
- VIMPATJuly 5, 2024 · NOC 33562 · Supplement to a New Drug Submission (SNDS)
- BIMZELXMarch 11, 2024 · NOC 32868 · Supplement to a New Drug Submission (SNDS)
- BIMZELXFebruary 23, 2024 · NOC 32765 · Supplement to a New Drug Submission (SNDS)
- BIMZELXJanuary 23, 2024 · NOC 32651 · Supplement to a New Drug Submission (SNDS)
- BRIVLERADecember 8, 2023 · NOC 32328 · Supplement to a New Drug Submission (SNDS)
- BIMZELXNovember 16, 2023 · NOC 32121 · Supplement to a New Drug Submission (SNDS)
- BIMZELXMay 30, 2023 · NOC 30906 · Supplement to a New Drug Submission (SNDS)
- BRIVLERAApril 14, 2023 · NOC 30521 · Supplement to a New Drug Submission (SNDS)
- KEPPRAMarch 9, 2023 · NOC 30291 · Supplement to a New Drug Submission (SNDS)
- NEUPROFebruary 8, 2023 · NOC 30076 · Supplement to a New Drug Submission (SNDS)
- BIMZELXJanuary 16, 2023 · NOC 29946 · Supplement to a New Drug Submission (SNDS)
- VIMPATJanuary 5, 2023 · NOC 29842 · Supplement to a New Drug Submission (SNDS)
- VIMPATSeptember 16, 2022 · NOC 28988 · Supplement to a New Drug Submission (SNDS)
- BRIVLERAAugust 26, 2022 · NOC 28830 · Supplement to a New Drug Submission (SNDS)
- BRIVLERAAugust 18, 2022 · NOC 29221 · Supplement to a New Drug Submission (SNDS)
- BIMZELXFebruary 14, 2022 · NOC 27593 · New Drug Submission (NDS)
- KEPPRANovember 30, 2021 · NOC 27130 · Supplement to a New Drug Submission (SNDS)
- VIMPATAugust 5, 2021 · NOC 26386 · Supplement to a New Drug Submission (SNDS)
- BRIVLERAJune 30, 2021 · NOC 26185 · Supplement to a New Drug Submission (SNDS)
- NEUPROMarch 11, 2021 · NOC 25421 · Supplement to a New Drug Submission (SNDS)
- KEPPRADecember 22, 2020 · NOC 24867 · Supplement to a New Drug Submission (SNDS)
- BRIVLERAMarch 24, 2020 · NOC 23693 · Supplement to a New Drug Submission (SNDS)
- CIMZIANovember 13, 2019 · NOC 22897 · Supplement to a New Drug Submission (SNDS)
- CIMZIAFebruary 8, 2019 · NOC 21838 · Supplement to a New Drug Submission (SNDS)
- CIMZIAAugust 16, 2018 · NOC 21220 · Supplement to a New Drug Submission (SNDS)
- NEUPRONovember 1, 2017 · NOC 19984 · Supplement to a New Drug Submission (SNDS)
- NEUPROAugust 11, 2017 · NOC 19649 · Supplement to a New Drug Submission (SNDS)
- CIMZIAJuly 4, 2017 · NOC 19486 · Supplement to a New Drug Submission (SNDS)
- BRIVLERAMay 25, 2017 · NOC 19353 · Supplement to a New Drug Submission (SNDS)
- VIMPATApril 18, 2017 · NOC 19182 · Supplement to a New Drug Submission (SNDS)
- CIMZIAMarch 10, 2017 · NOC 19042 · Supplement to a New Drug Submission (SNDS)
- VIMPATFebruary 28, 2017 · NOC 19011 · Supplement to a New Drug Submission (SNDS)
- BRIVLERAMarch 9, 2016 · NOC 17859 · New Drug Submission (NDS)
- CIMZIAJune 12, 2015 · NOC 17028 · Supplement to a New Drug Submission (SNDS)
- CIMZIAJanuary 15, 2014 · NOC 15120 · Supplement to a New Drug Submission (SNDS)
- CIMZIAJanuary 2, 2014 · NOC 15092 · Supplement to a New Drug Submission (SNDS)
- NEUPROMarch 21, 2013 · NOC 14234 · New Drug Submission (NDS)
- VIMPATMarch 4, 2013 · NOC 14173 · Supplement to a New Drug Submission (SNDS)
- VIMPATSeptember 27, 2012 · NOC 13681 · Supplement to a New Drug Submission (SNDS)
- CIMZIAAugust 10, 2012 · NOC 13551 · Supplement to a New Drug Submission (SNDS)
- VIMPATSeptember 30, 2010 · NOC 11767 · New Drug Submission (NDS)
- KEPPRAApril 23, 2010 · NOC 11287 · Supplement to a New Drug Submission (SNDS)
- KEPPRAJanuary 13, 2010 · NOC 10932 · New Drug Submission (NDS)
- CIMZIAAugust 12, 2009 · NOC 10498 · New Drug Submission (NDS)